Pink SheetThe UK’s originator drugs and generics industries are at odds over a rise in the clawbacks that companies must pay the government on the sales of branded medicines to the National Health Service under
ScripMerck KGaA only has two-late stage candidates in its pipeline but CEO Belén Garijo has told Scrip that the German company is laser-focused on adding more assets. Speaking at Merck’s annual press con
ScripIn the highly competitive race to follow Madrigal to market in metabolic dysfunction-associated steatohepatitis (MASH), perhaps the two most closely watched drug classes are the GLP-1 agonists, which
Pink SheetA pilot project run by the International Coalition of Medicines Regulatory Authorities to make it easier for companies to request post-approval manufacturing changes has resulted in positive outcomes,